INBX vs. MRUS, FTSV, RVMD, EXEL, HALO, CRSP, KRYS, IBRX, IMVT, and SWTX
Should you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Merus (MRUS), Forty Seven (FTSV), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), and SpringWorks Therapeutics (SWTX). These companies are all part of the "medical" sector.
Inhibrx (NASDAQ:INBX) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.
Merus has a net margin of -390.36% compared to Inhibrx's net margin of -13,408.95%. Merus' return on equity of -44.13% beat Inhibrx's return on equity.
In the previous week, Merus had 21 more articles in the media than Inhibrx. MarketBeat recorded 27 mentions for Merus and 6 mentions for Inhibrx. Inhibrx's average media sentiment score of 0.78 beat Merus' score of 0.41 indicating that Inhibrx is being referred to more favorably in the media.
Inhibrx presently has a consensus price target of $27.00, indicating a potential upside of 66.15%. Merus has a consensus price target of $63.80, indicating a potential upside of 19.83%. Given Inhibrx's higher probable upside, equities analysts plainly believe Inhibrx is more favorable than Merus.
Merus received 299 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 65.61% of users gave Merus an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
82.5% of Inhibrx shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 22.2% of Inhibrx shares are held by company insiders. Comparatively, 4.6% of Merus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Merus has higher revenue and earnings than Inhibrx. Merus is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
Inhibrx has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500. Comparatively, Merus has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
Summary
Merus beats Inhibrx on 12 of the 18 factors compared between the two stocks.
Get Inhibrx News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
